Erlotinib Plus Bevacizumab Phase ll Study in Patients with Advanced Non-small-Cell Lung Cancer (JO25567): Updated Safety Results

INTRODUCTION: The phase II JO25567 study compared the efficacy and safety of erlotinib plus bevacizumab vs. erlotinib alone as first-line therapy for advanced epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC). OBJECTIVE: Our objective is to provide updated...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Drug Saf
Main Authors: Kato, Terufumi, Seto, Takashi, Nishio, Makoto, Goto, Koichi, Yamamoto, Noboru, Okamoto, Isamu, Tao, Liang, Yu, Wei, Khaznadar, Tarik, Tajima, Kosei, Shibata, Masahiko, Seki, Akihiro, Yamamoto, Nobuyuki
Formato: Artigo
Idioma:Inglês
Publicado em: Springer International Publishing 2017
Assuntos:
Original Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5808045/
https://ncbi.nlm.nih.gov/pubmed/29043496
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40264-017-0596-0
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados